Core Viewpoint - Immunic, Inc. is actively participating in several investor and scientific conferences in June 2025 to present its clinical pipeline and engage with investors [1][3]. Conference Participation - Immunic will present at the Jefferies Healthcare Conference from June 3-5, with CEO Daniel Vitt providing a company overview on June 5 at 4:55 pm ET [1]. - The company will also participate in the 4th RSC Anglo-Nordic Medicinal Chemistry Symposium from June 10-13, where preclinical data on antiviral candidates will be presented [1][3]. - Attendance at the UBS Life Sciences Conference in London is scheduled for June 11, with opportunities for one-on-one meetings [1]. - Immunic's management will engage in partnering activities at the BIO International Convention from June 16-19 in Boston [1]. - The 11th Congress of the European Academy of Neurology will take place from June 21-24 in Helsinki, where data on vidofludimus calcium will be presented [1][3]. - The Accelerating Bio-Innovation Conference will be attended by Dr. Vitt and Mr. Tardio from June 23-25 in Cambridge, MA [1]. Company Overview - Immunic, Inc. focuses on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [3]. - The lead program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [4]. - Vidofludimus calcium acts as a first-in-class nuclear receptor related 1 (Nurr1) activator, providing neuroprotective effects and anti-inflammatory properties [4]. - Other candidates include IMU-856, targeting Sirtuin 6 (SIRT6) for gastrointestinal diseases, and IMU-381, currently in preclinical testing [4].

Core Insights - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [2][3] - The company is actively participating in several scientific and industry conferences in May 2025 to present its research and findings [1][2] Conference Participation - Immunic will present two abstracts at the Digestive Disease Week (DDW) from May 3-6, 2025, in San Diego, CA, focusing on its phase 1/1b clinical trial of IMU-856 for celiac disease [2] - A case study on clinical trial supply chain challenges in the Middle East and North Africa (MENA) will be presented at the Clinical Trial Supply Forum 2025 in Brussels, Belgium, from May 13-15, 2025 [2] - The company will also attend the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting 2025 in Phoenix, AZ, from May 28-31, 2025, where preclinical data on vidofludimus calcium (IMU-838) will be showcased [2] Product Development - The lead development program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis, with completion expected in 2026 [3] - IMU-856 targets SIRT6 to restore intestinal barrier function and has potential applications in various gastrointestinal diseases, including celiac disease and inflammatory bowel disease [3] - IMU-381 is a next-generation molecule currently in preclinical testing aimed at addressing gastrointestinal diseases [3]